

Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study

Yong-ho Lee,^{1,2†} Namki Hong,^{1,3†}, Chan Joo Lee,^{4,5} Sung Ha Park,^{4,5} Byung-Wan Lee,^{1,2}
Bong-Soo Cha,^{1,2} Eun Seok Kang^{1,2*}

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722.

²Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722.

³Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722.

⁴Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

⁵Cardiovascular Research Institute and Cardiovascular Genome Center, Yonsei University College of Medicine, Seoul, Republic of Korea


†These authors contributed equally to the study

Correspondence: Eun Seok Kang, MD, PhD


Department of Internal Medicine, Yonsei University College of Medicine,

50-1, Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea, 03722

Tel +82 2 2228 1968 ; Fax +82 2 393 6884 ; Email: edgo@yuhs.ac




A. Diabetes




B. No diabetes

Supplemental Figure 1. Comparison of propensity score distribution before and after matching as stratified by presence of diabetes. S and S+E represent simvastatin 20mg group and simvastatin 20mg + ezetimibe 10mg group, respectively.



A. Diabetes



B. No diabetes

Supplemental Figure 2. Plot of absolute standardized differences for covariates before and after propensity matching between patients treated with combination of ezetimibe 10mg + simvastatin 20mg and those treated with simvastatin 20mg monotherapy (A) in patient with diabetes and (B) in patients without diabetes